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OBJECTIVES We assessed the effect of angiotensin-converting enzyme (ACE) inhibition in combination
with a subthreshold preconditioning (PC) stimulus to elicit delayed preconditioning against
infarction in pig myocardium.
BACKGROUND Bradykinin triggers early PC. Angiotensin-converting enzyme inhibitors increase local
bradykinin levels via inhibition of kinin breakdown and have been shown in experimental
studies to augment early protection afforded by PC. A role for bradykinin in eliciting delayed
PC has not so far been identified.
METHODS We used a two-day protocol. On day 1 (closed chest), pigs were either sham-operated (group
1) or preconditioned, using balloon catheter inflation of the left anterior descending (LAD)
coronary artery, with either a full (4 3 5 min PC, group 2) or subthreshold PC stimulus (2 3
2 min PC, group 3). Additional groups were pre-treated with perindoprilat (0.06 mg/kg i.v.)
before sham (group 4) or subthreshold PC (group 5). On day 2 (open chest), all pigs were
subjected to 40 min occlusion of the LAD followed by 3 h of reperfusion. Infarct size was
determined by tetrazolium staining.
RESULTS Group 1 had a mean infarct size of 42.8 6 3.2% of the risk zone. Preconditioning with 4 3
5 min reduced the infarct size to 19.5 6 3.9% (p , 0.05). Groups 3 and 4 had infarct sizes
not statistically different from group 1. However, combining perindoprilat with subthreshold
PC resulted in a significant limitation of the infarction (18.4 6 3.1% p , 0.05), comparable
with group 2.
CONCLUSIONS This is the first study to show that ACE inhibition can augment a mild ischemic stimulus to
induce a protected state 24 h later. (J Am Coll Cardiol 2001;37:1996–2001) © 2001 by the
American College of Cardiology
Ischemic preconditioning (PC) is a powerful adaptive re-
sponse whereby brief periods of ischemia confer increased
myocardial tolerance to a subsequent episode of lethal
ischemia. This protective response appears in two phases.
Protection is seen immediately after PC and is lost within 2
to 3 h. This early phase of protection, known as “classic”
PC, is followed 24 to 72 h later by a recurrence of protection
called “second window” PC or delayed PC (1,2). During
brief ischemia, numerous diffusible mediators are gen-
erated, including bradykinin, adenosine, catecholamines
and opioid peptides, all of which are known to trigger classic
PC (3–7).
Bradykinin is thought to play a particularly important role
in triggering classic PC. There is evidence that myocardial
ischemia leads to increased production of tissue bradykinin
(8). The cardioprotective effects of bradykinin were first
investigated in animal models in which angiotensin-
converting enzyme (ACE) inhibitors afforded protection
during episodes of ischemia and subsequent reperfusion
(4,9–11). It was hypothesized that the protective action of
ACE inhibitors was associated with inhibition of bradyki-
nin breakdown (11). This hypothesis has been confirmed
with the use of HOE140 (icatibant), a bradykinin B2
receptor antagonist that was shown to abolish such protec-
tion in animal models and in human myocardium (9,12,13).
At present, the mediators of delayed PC are incompletely
characterized. There is persuasive evidence that adenosine
and nitric oxide (NO) both contribute to trigger the
adaptation that results in delayed protection (14,15). We
have observed that exogenously administered bradykinin
can elicit protection against infarction 24 h later in rat
myocardium (16). Because it is now widely accepted that the
ACE inhibitors exert their effect in PC through increased
bradykinin levels, we developed a model to investigate the
influence on delayed PC of an ACE inhibitor, perindopri-
lat. Accordingly, we studied the delayed PC effect in pigs
using brief percutaneous transluminal coronary angioplasty
(PTCA) balloon inflation before a sustained coronary oc-
clusion insult 24 h later. We hypothesized that an ACE
inhibitor, when combined with a subthreshold PC stimulus
(2 3 2 min periods of ischemia), could augment myocardial
bradykinin levels sufficiently to trigger a significant delayed
cardioprotection in the pig myocardium.
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METHODS
Pigs (Large White crossed with Landrace) of either gender,
weighing 27 to 30 kg, were used for this study. All animals
were cared for according to the recommendations from the
Declaration of Helsinki and the Guiding Principles in the
care and use of animals.
Anesthesia. The experimental procedure encompassed two
days. On day 1, animals underwent coronary catheterization
for either control or a PC protocol. On day 2, 22 to 24 h
later, open-chest animals were subjected to acute myocardial
infarction. For each procedure, pigs were pre-medicated
with ketamine (10 mg/kg, intramuscularly) and diazepam
(1 mg/kg). Surgical anesthesia was induced with thiopen-
tone sodium 10 mg/kg intravenously (i.v.) and maintained
using a gaseous mixture of nitrous oxide/oxygen (ratio 2:3),
with 1.0% to 1.5% isoflurane. Standard limb electrocardio-
grams and systemic blood pressure (BP) were monitored
continuously and recorded at regular intervals using a
Seimens Sirecust hemodynamic monitor. Arterial pO2 and
pH were maintained within the physiologic range (120
to 160 mm Hg, 7.43 to 7.48 respectively) by adjusting
gaseous mixture ratio and the frequency of ventilation.
Coronary catheterization procedure (day 1). The right
carotid artery was isolated and cannulated with a 7F arterial
sheath for PTCA. Under angiographic guidance, a 6F
amplatz left 1 guiding catheter was inserted into the artery
and advanced down the carotid artery and the arch of aorta
and guided into the left coronary artery (LCA). Left
coronary angiography was then performed in oblique view
to delineate the LCA and its main branches. A 0.014-inch
floppy guide wire was pushed down the guiding catheter
and maneuvered such that it was positioned in the distal
LAD. An inflatable balloon catheter was inserted over the
floppy guide wire and positioned halfway to two-thirds
down the LAD as defined by the angiogram. Control
measurements were recorded and heparin was administered
(1,000 IU i.v.). Animals were randomly allocated to sham or
preconditioned groups. In the case of sham-operated ani-
mals, the balloon was not inflated. A sketch of the image
was made, marking the site of intended ligature as well as
the branches proximal and distal to the ligature. Precondi-
tioned animals underwent serial inflations (three bars) with
intermittent 10-min reperfusions (see Treatment Proto-
cols). A second angiogram ensured complete occlusion of
the LAD distal to the balloon. Electrocardiograms and BPs
were recorded before and after every balloon inflation. After
completion of the procedure, catheters were removed, tissue
and skin incisions were sutured, and the animal was extu-
bated upon establishing a regular breathing pattern. Each
pig received ampicillin 5,000 IU i.v., as well as heparin-
calcium 5,000 IU subcutaneously before being returned to
the pen.
Infarction procedure (day 2). The animal was pre-
medicated and anesthetized as described earlier. After sur-
gical anesthesia was established, a mid-line thoracotomy
was performed. The animal was placed on the operating
table in the same oblique position as on the previous day.
Using the sketch we were easily able to determine the
location of the balloon site bordered by the proximal and
distal branches. The LAD was then prepared and isolated
from the surrounding tissue at the same region as on day 1.
A 3-0 silk suture was passed around the isolated portion of
the LAD, and the ends of the thread were passed through
a small vinyl tube to form a snare. The right femoral artery
was cannulated for BP measurement and blood sampling.
Before the snare was tightened, the pig received heparin
1,000 IU i.v. and thereafter every hour throughout the
experiment. By tightening the snare, the LAD was occluded
for 40 min followed by 180 min of reperfusion. When
ventricular fibrillation (VF) occurred, direct-current cardio-
version was applied immediately. If defibrillation could not
be accomplished within 60 s, the experiment was termi-
nated. Ventricular tachycardia (VT) was defined as more
than four consecutive ventricular premature beats. Runs of
VF or VT were considered terminated if they were followed
by three or more normally conducted sinus beats.
Infarct size assessment. After 180 min of reperfusion, the
LAD was ligated at the same location. To identify the risk
zone, 5 ml patent blue (7.5%) solution (May & Baker,
United Kingdom) in saline was injected into the left atrium.
The heart was then excised, total left ventricular mass was
recorded, and the risk zone (not stained) was isolated layer
by layer. To ensure anatomical consistency of the ischemic
risk zone, a predetermined exclusion criterion was a risk
zone ,15% or .30% of LV. The risk zone was sectioned at
3-mm thickness from apex to base. Slices were incubated in
1% triphenyltetrazolium chloride at 37°C for 15 min and
fixed in 10% formalin for 24 to 48 h to enhance the contrast
between viable and infarcted myocardium. The boundaries
of the infarcted regions were traced onto acetate sheets and
assessed by computerized planimetry (Summa Sketch II,
Summa Graphics). The volumes of infarcted and risk zones
were calculated by multiplication of each area with the
thickness of the slice.
Treatment protocols. Treatment protocols are illustrated
in Figure 1. There were five experimental groups. On day 2,
all animals were anesthetized and subjected to 40 min
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
BP 5 blood pressure
i.v. 5 intravenously
LAD 5 left anterior descending coronary artery
LCA 5 left coronary artery
NO 5 nitric oxide
PC 5 ischemic preconditioning
PTCA 5 percutaneous transluminal coronary
angioplasty
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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coronary artery occlusion and 180 min reperfusion. Pre-
treatment on day 1 was as indicated.
GROUP 1: CONTROL. Animals were anesthetized on day 1
and instrumented for coronary catheterization but were not
preconditioned.
GROUP 2: DELAYED PC. Animals underwent coronary cath-
eterization and a full PC stimulus consisting of four 5-min
balloon inflations with 10 min intermittent deflation (4 3 5
PC).
GROUP 3: SUBTHRESHOLD PC. On day 1, pigs were sub-
jected to two cycles of 2-min balloon inflation (ischemia)
with an intermittent deflation given as the subthreshold
stimulus (2 3 2 PC).
GROUP 4: PERINDOPRILAT. Pigs were subjected to the con-
trol procedure as in group 1 but received perindoprilat
0.06 mg/kg i.v., a dose that we previously demonstrated
would decrease plasma ACE levels in pigs by .95% (17).
GROUP 5: PERINDOPRILAT 1 SUBTHRESHOLD PC. On day 1,
pigs were subjected to two cycles of 2-min balloon inflation
(ischemia) with an intermittent deflation given as the
subthreshold stimulus (2 3 2 PC); 20 min before the first
balloon inflation, pigs were given perindoprilat 0.06 mg/kg
i.v.
Statistical analysis. All results are expressed as mean val-
ues 6 SEM. Infarct-size data were analyzed with one-way
analysis of variance (ANOVA) followed by unpaired t test
with Bonferroni’s correction for multiple comparisons. He-
modynamic data were analyzed using repeated-measures
ANOVA. The null hypothesis was rejected when p , 0.05.
RESULTS
Exclusions. A total of 54 pigs were used in this study.
Fifteen pigs were excluded from final infarct analysis for the
following reasons. Two animals were excluded because of air
embolism in the coronary arteries during PTCA. Four
animals were excluded as a result of VF lasting .60 s. Five
animals were excluded after opening the chest on day 2,
when they were found to have evidence of old or recent
infarction. One pig was excluded because of the presence of
pericarditis on day 2. Three hearts were excluded because
the risk zone was ,15% of LV. The final numbers in each
group were as follows: group 1, n 5 9; group 2, n 5 8; group
3, n 5 7; group 4, n 5 8; group 5, n 5 7.
Hemodynamic data. There were no significant differences
in heart rate, systemic BPs (not shown) or rate/pressure
product among the five groups. Table 1 summarizes changes
in heart rate and rate pressure products, an index of
myocardial oxygen consumption, at selected intervals during
both day 1 and day 2 of the experiments.
Risk zone and infarct size. Ischemic risk zone volume and
infarct size are shown in Figure 2. Risk zone size was
expressed as a percentage of total left ventricular mass.
Figure 2a shows that the ischemic risk zone size was similar
in all experimental groups at around 21% to 24% of LV
mass. Infarct size as a percentage of the risk zone is shown
in panel b. Sham-operated control pigs (group 1) had a
mean infarct size of 42.8 6 3.2% of the risk zone. Precon-
ditioning with four 5-min coronary occlusion episodes
limited the infarction to 19.5 6 3.9% (p , 0.05). The
milder PC stimulus (group 3) did not lead to statistically
significant infarct limitation (33.4 6 3.9%). Pre-treatment
of pigs on day 1 with perindoprilat (group 4) resulted in a
small but non-significant reduction in infarct size (31.2 6
2.3%). This may be a reflection of the long biological
half-life of perindoprilat. In group 5, when we combined
subthreshold PC stimulus of 2 3 2 min balloon inflations in
the presence of the ACE inhibitor perindoprilat, significant
cardioprotection was observed (18.4 6 3.1%), comparable
with that observed in the 4 3 5 PC protocol (19.5 6 3.9%).
Thus, protection against infarction was observed 24 h after
a full PC stimulus (group 2) or after a subthreshold PC
stimulus augmented by perindoprilat (group 5). This pro-
tection was clearly independent of variations in risk-zone
size. Further, because we and others have shown that the pig
has a poorly developed native coronary collateral circulation
(18,19), it is unlikely that infarct limitation is due to altered
collateral flow.
Arrhythmias. Arrhythmias during the PC procedure on
day 1 were rare and minor in nature. Figure 3 summarizes
the incidence of VF during the 40-min coronary-occlusion
period and 180-min reperfusion period on day 2. Although
the majority of animals in all groups experienced some form
of ventricular premature beats and/or VT (data not shown),
their extent was highly variable, and no specific pattern
could be determined. Fewer animals had VF during the
ischemia-reperfusion period. Overall, there were no statis-
tically significant differences in VT or VF across the groups,
although there was a tendency to less reperfusion VF in
group 2 and group 4.
Figure 1. Experimental protocols. For details, see text. Perindopril
0.06 mg/kg i.v. was given in groups 4 and 5 (arrow).
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DISCUSSION
In this study, we have observed a delayed ischemic PC effect
in pig myocardium associated with limitation of infarct size
24 h after a PC event. Moreover, we found that a milder PC
protocol, when combined with an ACE inhibitor, was as
protective as a full PC stimulus.
Delayed PC against infarction in pig heart. Although the
antistunning effects of delayed PC in pig myocardium are
well characterized (15,20), this is the first study to show that
delayed PC against infarction can be elicited in pig myo-
cardium. Two previous studies did not observe a statistically
significant limitation of infarction 24 h later (20,21). The
extent of infarct-size limitation observed in the present
study is similar to that seen in all other species in which
delayed PC has been shown (22).
Figure 2. Infarct size. a: infarct-to-risk zone ratio; b: risk zone-to-LV
ratio. *p , 0.01 versus group 1 (sham-operated control) (one-way analysis
of variance).
Figure 3. Incidence of ischemia and reperfusion-induced VF during the
infarct protocol (day 2). Differences are not statistically significant.Ta
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ACE inhibition and classic PC. A number of reports
point to the efficacy of bradykinin in mediating acute
cardioprotective effects against various end points of injury
in several other animal models, including rabbits, rats and
dogs (23–30). Taken together, these studies strongly suggest
that bradykinin, generated during the brief periods of PC
ischemia, plays a major role in triggering the cellular events
that ultimately result in short-term protection of the isch-
emic myocardium in some species, that is, classic PC.
However, a number of autocrine and paracrine substances,
including adenosine, bradykinin, catecholamines and opioid
peptides, act in concert to induce the final cardioprotective
effects of PC. There is sufficient redundancy in the system to
allow for cardioprotection by other mechanisms when any
individual trigger is inhibited. This “threshold” hypothesis
proposed by Downey’s group (25) was based on a study in
which pre-treatment with the bradykinin B2-receptor an-
tagonist HOE140 abolished protection from ischemic PC
with 5 min of ischemia and 10 min of reperfusion, but not
when the PC stimulus was four cycles of 5-min ischemia/
10-min reperfusion. The hypothesis was tested in human
myocardium (13), where we demonstrated that a subthresh-
old PC stimulus was able to precondition human myocar-
dium in the presence of ACE inhibition and that the
protective effects observed were directly due to bradykinin.
ACE inhibition and delayed PC. With regard to delayed
PC, three principal diffusible molecular triggers have been
identified: adenosine, NO and reactive oxygen species (22).
In rabbit studies, blockade of adenosine receptors with a
pharmacological inhibitor during PC resulted in a loss of
protection 24 h later. Conversely, administration of a
short-acting selective adenosine A1 agonist led to infarct-
size limitation 24 h later (14). A similar trigger role for NO
has been identified through a similar investigative approach
(15). It has been proposed that NO and superoxide anion
generated in response to PC ischemia combine to form
peroxynitrite anion, which is a key signaling intermediate
leading to the activation of protein kinase C and down-
stream kinases. The ability of bradykinin to modulate NO
production is well established, and it is possible that
bradykinin release may be an important early event preced-
ing the generation of NO. Recently, we have found that
exogenously administered bradykinin triggers a delayed PC
effect in rat heart (16). This sub-acute action of bradykinin
was abolished by NO synthase inhibition. The results of the
present study are consistent with a role for bradykinin in
triggering delayed PC. However, in the absence of any
direct measurements of bradykinin concentration in tissue
or coronary sinus blood, or of studies with bradykinin
receptor antagonists, we cannot conclusively implicate bra-
dykinin at this stage. Angiotensin-converting enzyme (ki-
ninase II) is known to cleave many substrate peptides other
than angiotensin I and kinins. Other substrates include
enkephalins and the partially processed peptide hormone
pro-enkephalin, as well as substance P (31). Inhibition of
ACE could therefore augment those peptide mediators that
might contribute to triggering the PC effect. This limitation
of the present study should be addressed in further studies.
Implications for ACE-inhibitor therapy. Angiotensin-
converting enzyme inhibitors were introduced as antihyper-
tensive agents. However, they have been shown convinc-
ingly to decrease mortality in patients with congestive heart
failure by reducing pre-load, after-load and systolic wall
stress, thus resulting in increased cardiac output without an
increase in heart rate (32–35). Large clinical trials have also
indicated that ACE inhibitors reduce mortality and reduce
ventricular dysfunction after acute myocardial infarction
(36,37), limiting left ventricular remodeling as well as
myocardial ischemic events. More recently, the HOPE
study clearly demonstrated that the ACE inhibitor ramipril
significantly lowered the risk of major cardiovascular out-
comes by 25% to 30% in a large cohort of high-risk patients
(38). Interestingly, the risk reduction for cardiovascular
events was greater than would be expected from the ob-
served mean difference in BP between groups, which sug-
gests that the effects of ACE inhibition in this study were
greater than could be attributed to its effect on lowering BP.
We hypothesize that the cardioprotective effects of ACE
inhibitors could, at least in part, be a consequence of the
ability of endogenous bradykinin to initiate both classic and
delayed PC effects. Moreover, some ACE inhibitors have
been shown to exert direct infarct-limiting effects in exper-
imental models, independent of their ability to augment PC
(10,12,39,40). Indeed, in this study, treatment with perin-
doprilat, which has a long biological half-life, 24 h before
infarction resulted in a small, although non-significant,
protective effect. The infarct-limiting effects of short-term
administration of perindoprilat during the infarct-associated
coronary occlusion may warrant further investigation.
In conclusion, an ACE inhibitor, in conjunction with a
mild ischemic stimulus, served as an effective trigger of
delayed PC against subsequent infarction in pig myocar-
dium. This finding may reflect a contributory mechanism by
which ACE inhibition exhibits beneficial effects in patients
with ischemic heart disease.
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